Dermatology Times April 2025 Recap

Clearances, Approvals, Updates, and Recommendations

FDA Approves Dupilumab for Adolescents and Adults With H1 Antihistamine-Refractory Chronic Spontaneous Urticaria

Dupilumab becomes the first targeted therapy approved for chronic spontaneous urticaria in more than a decade.

AbbVie Files BLA for TrenibotE in Glabellar Lines

AbbVie seeks FDA approval for TrenibotE, a first-in-class botulinum toxin offering fast onset and short duration for glabellar lines.

FDA Approves First Gene Therapy for RDEB

The FDA approved pz-cel, a groundbreaking gene therapy for recessive dystrophic epidermolysis bullosa, transforming treatment options for patients.

Big Studies and Big Data

Guselkumab Demonstrates Impact on Both Disease Progression and Symptoms in Psoriatic Arthritis

Tremfya is the first IL-23 inhibitor to significantly improve both symptoms and structural damage in active psoriatic arthritis.

Patient Survey Highlights Dissatisfaction and Undertreatment in Hidradenitis Suppurativa Care

A cross-sectional survey revealed that many patients with HS are dissatisfied with treatment options, with gaps in knowledge about FDA-approved therapies.

Icotrokinra Demonstrates Efficacy in Adolescents and Adults With Moderate to Severe Psoriasis in ICONIC-LEAD Phase 3 Study

A new subgroup analysis revealed higher rates of clear or almost clear skin at week 16 vs placebo with a favorable safety profile.

New Qtorin Rapamycin Data Featured at World Congress of Pediatric Dermatology

The presentation, led by Amy Paller, MS, MD, highlighted the upcoming phase 3 SELVA study for microcystic lymphatic malformations.

HyBryte Achieves 75% Treatment Success by Week 18 in Ongoing CTCL Trial

Interim FDA-funded study results show HyBryte delivers rapid, sustained response and strong safety in early-stage CTCL patients.

Gene Expression Profile Testing Offers Clinicians a Path to Safely Avoid SLNB in Low-Risk Melanoma Patients

New prospective data from the DECIDE study reinforce the role of the 31-GEP test in clinical decision-making.

Survey Unveils Impact of Chronic Hand Eczema on Patients’ Lives and Treatment Landscape

A survey by LEO Pharma indicates widespread misunderstandings about chronic hand eczema, revealing significant emotional and occupational challenges for patients.

Market, Pharma, and Specialty News

Exploring the 2025 Revolutionizing Atopic Dermatitis (RAD) Annual Meeting Agenda

Get a glimpse of the cutting-edge atopic dermatitis research, breakthroughs, and insights to be presented at the 7th RAD Annual Meeting, June 6-7, 2025.

Alphyn Doses First Patient in Phase 2b Trial for Zabalafin Hydrogel

Alphyn Biologics has dosed the first patient in a global phase 2b trial of zabalafin hydrogel for mild to moderate atopic dermatitis.

Evommune Advances EVO756 Into Global Phase 2b Trial for Chronic Spontaneous Urticaria

Evommune has initiated a global phase 2b trial of EVO756, a first-in-class MRGPRX2 antagonist, for moderate to severe CSU.

Attovia Closes $90 Million Series C Financing for ATTOBODY Programs

The funds will target programs for chronic pruritus, atopic dermatitis, and other inflammatory skin conditions.

Palvella Secures New US Patent for Qtorin Rapamycin in Microcystic Lymphatic Malformations

Palvella has secured its 5th US patent for Qtorin rapamycin, extending intellectual property coverage to 2038 and advancing treatment for microcystic lymphatic malformations.

Channel Therapeutics and Pelthos Therapeutics to Merge to Accelerate Launch of Zelsuvmi for Molluscum Contagiosum

Pelthos and Channel Therapeutics will merge to form a new publicly traded entity focused on commercializing the first at-home treatment for molluscum.

FDA Places Clinical Hold on VYNE’s VYN202 Phase 1b Trial for Plaque Psoriasis

VYNE Therapeutics paused its VYN202 trial for psoriasis due to an FDA-issued clinical hold.

Strides for Skin Health Equity

High-Intensity Ultrasound Device Is Suitable for Facial Acne Scars in Asian Patients

Nearly all patients saw improvements in small, medium, and large depressions on the cheeks and temples with just a singular treatment session.

Allergan Aesthetics' Effort to Create a Unified Vocabulary for Skin Quality

Sherket Peterson, PhD, spoke to Dermatology Times about Allergan’s recent research and plan to launch a universal skin quality index.

How Anastasia Georgievskaya and SkinGPT Are Addressing Gaps in the Dermatology Industry

Haut.AI’s new tool promotes inclusive and realistic conversations on the power of skincare products, according to the CEO.

Subgroup Case Series Reveals JAKi Efficacy for Black Patients With AA

JAK inhibitors show promise in treating alopecia areata among Black patients, highlighting the need for inclusive clinical research and equitable access to therapies.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.